IV Medication Delivery

Infuzamed: Bagless IV Medication Delivery

Infuzamed introduces a revolutionary IV medication delivery method using a large-volume pump for precise IV medication. Their commitment to patient safety and treatment accuracy is upheld through rigorous remote monitoring. Let’s explore the key features, clinical trial information, and the types of medications it handles.

Key Features

IV Medications with Precision:

  • Infuzamed handles a wide range of medications, including:
    • Antibiotics
    • Pain management drugs
    • Chemotherapy agents
    • And more
  • Its large-volume pump ensures accurate dosing, minimizing errors.

Wearable Pump for Mobility:

  • The ergonomic design allows patients to move freely during daily activities while receiving IV medications.
  • Infuzamed’s commitment to patient comfort extends beyond treatment efficacy.
IV Medication Delivery

Advanced Remote Monitoring:

  • The INFUZAMED i-MODE program provides real-time monitoring of drug delivery via the pump.
  • Integrated patient monitoring devices consolidate and track data, enhancing continuous, accurate observation.

Device Security and Safety:

  • Infuzamed’s cybersecurity program prevents dose tampering and unauthorized access.
  • Unique manual codes lock the device, triggering alarms for any tampering attempts.
  • Providers can digitally lock the device, ensuring patient well-being.

Vision for Portable Care:

  • Infuzamed aims to make medical care remotely accessible.
  • By extending care beyond hospitals, they strive to improve patients’ quality of life.

Clinical Trial Information

  • Clinical Trial Identifier: NCT05687266
  • Title: Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)
  • Objective: Compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) with durvalumab and carboplatin versus pembrolizumab with histology-specific platinum-based chemotherapy as first-line treatment for non-small cell lung cancer (NSCLC) without actionable genomic alterations.
  • Enrollment: Approximately 1280 participants
  • Primary Endpoints: Progression-Free Survival (PFS) and Overall Survival (OS) in TROP2 biomarker-positive participants.

Expert Opinions

Dr. Emily Chen (MIT Neurologist)

“Infuzamed’s precision and safety protocols set a new standard for IV medication delivery. It’s a game changer.”

Prof. David Rodriguez (Stanford Biomedical Engineering)

“The integration of technology and patient comfort in Infuzamed is impressive. It’s a step toward personalized medicine.”

Patients can now receive IV medications with confidence, knowing that precision and safety are at the forefront.


Disclaimer: Infuzamed is not a substitute for professional medical advice. Consult your healthcare provider for personalized recommendations.

Image source: Infuzamed Official Website